BeiGene (BGNE) Stock Forecast & Price Target

BeiGene - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 8 Analyst Ratings

Sell
0

Hold
2

Buy
6

Consensus Price Target

$253.69
N/A

Get the Latest News and Ratings for BGNE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for BeiGene and its competitors.

BGNE Analyst Ratings Over Time

Type	Current Forecast 2/3/24 to 2/2/25	1 Month Ago 1/4/24 to 1/3/25	3 Months Ago 11/5/23 to 11/4/24	1 Year Ago 2/3/23 to 2/3/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	6 Buy rating(s)	5 Buy rating(s)	8 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$253.69	$253.69	$246.21	$272.90
Forecasted Upside	N/A	37.34% Upside	18.80% Upside	88.88% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

BGNE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BGNE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

BeiGene Stock vs. The Competition

Type	BeiGene	Medical Companies	S&P 500
Consensus Rating Score	2.75	2.82	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	N/A	15,295.31% Upside	12.26% Upside
News Sentiment Rating	Neutral News See Recent BGNE News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/3/2024	Morgan Stanley 3 of 5 stars		Reiterated Rating	Overweight	$300.00	+45.81%
11/13/2024	TD Cowen 5 of 5 stars		Boost Target	Buy ➝ Buy	$254.00 ➝ $260.00	+32.21%
10/22/2024	JPMorgan Chase & Co. 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$200.00 ➝ $235.00	+7.12%
9/18/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Benjamin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$288.00	+45.82%
8/8/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$269.00 ➝ $288.00	+57.06%
7/9/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$180.00 ➝ $152.50	+5.82%
3/27/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Market Perform ➝ Market Perform	$196.00 ➝ $161.00	+4.67%
2/27/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$350.00 ➝ $345.00	+98.62%
9/12/2023	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$259.00	+25.82%
9/11/2023	Macquarie Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$259.00	+23.78%
Get the Latest News and Ratings for BGNE and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.
8/17/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$287.00	+49.22%
6/30/2023	51job Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Downgrade
6/30/2023	22nd Century Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Downgrade
6/30/2023	3M Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Downgrade
2/28/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$213.00 ➝ $262.00	+21.28%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 03:37 AM ET.

Should I Buy BeiGene Stock? BGNE Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, January 25, 2025. Please send any questions or comments about these BeiGene pros and cons to contact@marketbeat.com.

BeiGene
Bull Case

Here are some ways that investors could benefit from investing in BeiGene, Ltd.:

Current stock price is $191.78, indicating a strong market position and potential for growth.
Institutional ownership is at 49.13%, suggesting confidence from large investors in the company's future performance.
Recent increase in shares shorted from 2,010,000 to 2,250,000 indicates heightened interest, which could lead to a short squeeze, benefiting long investors.
Average daily volume of 271,300 shares shows good liquidity, allowing investors to enter and exit positions with ease.
Despite a slight decline in the fifty-two week performance of -5.44%, this could present a buying opportunity for investors looking for undervalued stocks.

BeiGene
Bear Case

Investors should be bearish about investing in BeiGene, Ltd. for these reasons:

Shares shorted have increased significantly, which may indicate negative sentiment among some investors regarding the company's future prospects.
With a float size of 0, it suggests that there are no shares available for trading, which can lead to volatility and difficulty in executing trades.
Recent performance shows a month-to-month change percentage of 11.94%, which, while positive, may indicate instability in stock price movements.
Outstanding shares total 92,010,000, which can dilute earnings per share if the company issues more shares in the future.
Short percentage of float is 0%, indicating that there are no shares available for short selling, which can limit trading strategies for some investors.

BGNE Forecast - Frequently Asked Questions

: According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for BeiGene is $253.69, with a high forecast of $345.00 and a low forecast of $152.50.
: 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BGNE shares.
: According to analysts, BeiGene's stock has a predicted upside of ∞ based on their 12-month stock forecasts.
: BeiGene has been rated by research analysts at Morgan Stanley, and TD Cowen in the past 90 days.
: Analysts like BeiGene less than other "medical" companies. The consensus rating score for BeiGene is 2.75 while the average consensus rating score for "medical" companies is 2.82. Learn more on how BGNE compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This page (NASDAQ:BGNE) was last updated on 2/2/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BeiGene (BGNE) Stock Forecast & Price Target